An antibody construct developed by Affimed NV of Germany has generated objective responses from a small group of lymphoma patients – all of whom had exhausted all available treatment options. The Phase 1/2 investigator-led study is being conducted at the University of Texas MD Anderson Cancer Center in the US. Updated clinical data were presented at the annual meeting of the American Association for Cancer Research in April.
